Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.